Industrial biotechnology can reduce greenhouse gas emissions

The WWF report Industrial biotechnology – more than green fuel in a dirty economy?, which has been published today, concludes that industrial biotechnology can provide dramatic reductions in greenhouse gas emissions and provide strong progress toward a green and sustainable economy. WWF calls for increased political backing for the industry to leverage the positive environmental effects. The findings are based on peer-reviewed research from Novozymes, the world leader in bioinnovation, as well as contributions from experts and WWF.

WWF, the world’s biggest environmental NGO, has calculated that industrial biotechnology could generate between 1 and 2.5 billion tons of greenhouse gas reductions per year by 2030, as well as build a new green economy that cleverly works with nature to meet human needs.

“WWF sees industrial biotech as an industry that can play a very significant role in the development of a new, green economy if developed in the right way. The world can’t afford to ignore this opportunity,” says John Kornerup Bang, Head of Globalization Programme for WWF.

Industrial biotechnology is currently used to produce hundreds of everyday products, including detergents, textiles, bread, wine, beer, and bioethanol. For example, the use of modern enzymatic detergents has reduced washing temperatures from 60 to 30 degrees Celsius, saving millions of tons of CO2. However, the potential of industrial biotechnology is much greater and includes a transformation of our economy. The future could hold a bio-based economy in which biorefineries outcompete petrochemicals by transforming waste products and other biomass into fermentable sugars to make energy as well as products that are currently made from oil. This could include everything from diapers to plastics.

Need for strong public policies

The report emphasizes that strong public policies must be in place to help realize the potential of industrial biotech and points out initiatives such as pollution costs charged to petrol-based materials, investment in advanced waste management technologies, and labeling systems for bio-based products. Novozymes agrees with WWF that strong public policies must be developed to challenge today’s conventions.

“In a few years sugar will be the new oil. Already today close to 200 biorefineries are operating in the US and yet we have only seen the beginning. Industrial biotechnology today is a sector with a number of pioneers who are demonstrating that this is technically feasible. However, to make the biobased economy into reality, they will require political backing. Novozymes is dedicated to helping ensure a radical shift in the way our societies work, and to reduce our dependency on oil,” says Steen Riisgaard, CEO of Novozymes.

Dramatic CO2 savings in four closely linked focus areas

In the report WWF outlines four key areas in which industrial biotechnology can provide radical emission cuts:

Notes to editors:

  • The 24-page policy paper Industrial biotechnology – more than green fuel in a dirty economy? , which contains the key findings as well as policy recommendations, can be downloaded at this address: www.divshare.com/download/8537942-24e
  • The detailed technical report GHG Emission Reductions With Industrial Biotechnology: Assessing the Opportunities, which provides the analysis and background for the conclusions, can also be found here: www.divshare.com/download/8537939-3e0

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications